Alopecia Areata Video Perspectives
Emma Guttman-Yassky, MD, PhD
Disclosures
Guttman-Yassky reports financial relationships with AbbVie, Almirall, Amgen, AnaptysBio, Arena, Asana Biosciences, Aslan Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Bristol Meyers Squibb, Cara Therapeutics, Celgene, Connect Pharma, Eli Lilly, EMD Serono, Evidera, Galderma, Ichnos Sciences, Incyte, Innovaderm, Janssen Biotech, Kyowa Kirin, LEO Pharma, Novartis, Pandion Therapeutics, Pfizer, RAPT Therapeutics, Regeneron Pharmaceuticals, Sanofi, SATO Pharmaceutical, Siolta Therapeutics, Target Pharma Solutions, UCB and Ventyx Biosciences.
October 11, 2023
1 min watch
Save
VIDEO: Deciding when to refer patients with alopecia areata to clinical trials
Transcript
Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.
So, I like to talk to patients, I position to them what we can do through the insurance, for example, a patient that will have eczema as well. So, we can give Dupixent (dupilumab, Sanofi and Regeneron Pharmaceuticals) through the insurance, but if not, we'll do it through the clinical trial. And I tell them about available clinical trials and then I see what they want to do.
